MALIGNANT NEOPLASMS IN MOZAMBIQUE

A FREQUENCY RATIO SURVEY FROM 1944-DECEMBER 31, 1957 AND A COMPARISON WITH OTHER PARTS OF AFRICA

M. D. PRATES

From the Hospital Central Miguel Bombarda, Lourenço Marques, Portuguese East Africa

Received for publication April 2, 1958

During the last 25 years, several reports on the frequency ratio of malignant neoplasms among the African people have appeared from different parts of the African Continent (Pirie, 1921; Smith and Elmes, 1934; Strachan, 1934; Berman, 1935; Vint, 1935; des Ligneris, 1936; Prates, 1938; Elmes and Baldwin, 1947; Gelfand, 1948; Davies, 1948; Findlay, 1949; Higginson, 1951; Thijs, 1957; Wainwright, 1957). Apart from the study on liver cancer and cirrhosis (Prates, 1938), up to the present no information has been forthcoming concerning the cancer frequency ratios in Africans living in the Portuguese province of Mozambique on the East Coast of Africa.

Through the generous assistance of the National Cancer Association of South Africa, a cancer survey unit was established in Lourenço Marques almost two years ago in order to ascertain the risk to cancer for the African population in and around Lourenço Marques. As an essential preliminary to the main survey all the histological material collected in the pathological laboratory during the previous 13 years was analysed. It was hoped that such a preliminary analysis

might indicate the kinds of cancers to be expected in this city.

In view of the limited medical services and the paucity of cancer registries in the underdeveloped Continent of Africa, the greatest amount of information about cancer in Africa will continue to be derived, in the immediate future, from postmortem and hospital statistics. Although these statistics cannot allow any predictions to be made about the risk to cancer for the population as a whole, nevertheless, a comparison of the data accumulated in the hospital at Lourenço Marques over the last 13 years with the preliminary data of the rates survey conducted over a period of 19 months, will afford some indication of the site frequency of certain types of cancers and the potential value which can be attached to the data derived from conventional routine services of pathological laboratories and hospitals in regions where special cancer units and registries are still not available. Accordingly, it is proposed:

- 1. To report the kinds of cancers and their frequency ratios in all the material collected in Lourenco Marques during the past 13 years,
- 2. to compare these date with those accumulated during the 19-month period following the establishment of the Cancer Unit when interest in cancer was greatly stimulated, and
- 3. to compare the data from Lourenço Marques with those available from other territories in Africa. From this comparison, it will become

apparent that although there are some similarities, there are also marked differences in the site frequency of cancer in different parts of Africa suggesting that environmental influences may be operating in predisposing some sites to cancer more than others.

MATERIAL AND METHODS

The Province of Mozambique is situated between longitude 30° and 42° East and latitude 10° and 27° South and covers 297,731 square miles (771,255 square kilometres). According to the census of 1950, the population comprises 5,647,000 Africans (2,692,863 males and 2,954,137 females); 50,000 Europeans; 26,000 Coloureds; and 15,000 Asiatics. The medical service, including hospitalisation, is provided free for all Africans, for all the other racial groups earning a salary of less than £30 per month and for all civil servants.

Table I.—The Number of In-patients and Out-patients of the Lourenço Marques Hospital for the Year 1956

In-	pati	ents	
Europeans			3,263
Africans			13,246
Coloured	•		1,258
Total			17,767
Out-	pat	ients	
Europeans			26,374
Africans			47,560
Coloured	•	•	7,629
Total			81,563

The largest hospital in the Province is located in Lourenço Marques and has about 1000 beds for Africans. The in-patients' turnover in 1956 was 13,246 Africans, 3263 Europeans and 1258 Coloureds and Asiatics. Of the female inpatients 5230 were admitted to the maternity wards. If allowance is made for maternity cases, then three-quarters of the in-patients are males, and only one-quarter females.

47,560 Africans, 26,374 Europeans, and 7629 Coloureds and Asiatics sought treatment in the outpatients' department during 1956 (Table I). It should be mentioned that all the pathological material from Mozambique is sent to the hospital "Miguel Bombarda" (Lourenço Morques' hospital) for examination. The greatest number of examinations are conducted for in-patients as well as outpatients in the Lourenço Marques Hospital, and, to a lesser extent, for patients distributed widely throughout the entire province. It follows that the greatest number of cancers are derived from patients treated in and around Lourenço Marques. The material as a whole is more representative of the people inhabiting the South than of those living in the Central and Northern regions.

The rates survey is being conducted on a population of African people numbering approximately 100,000, living in the city and environs of Lourenço Marques.

Prior to the middle of 1956, a total of 1606 malignant neoplasms was diagnosed from autopsy and histological examination. In May 1956, the special survey was

initiated. During the past 19 months, a total of 371 malignant tumours was diagnosed by autopsy and histological examination. Tumours diagnosed by any other method, e.g. radiological or clinical, are not considered in the present study. Of the total of 371 tumours, 210 were found in patients not belonging to the population of Lourenço Marques under survey. That is to say, three groups of material were accumulated; the first from 1944 to 1956; the second obtained from all cancer patients seeking treatment at the Lourenço Marques Hospital from May 1956 to December 1957; while the third group included patients with malignant neoplasms belonging strictly to the area under survey from May 1956 to December 1957, inclusive. The total number of tumours recorded in Africans from May 1944 to December 31, 1957 was 1273. In addition, 580 tumours were identified in Europeans and 124 tumours in Coloureds and Asiatics making a total of 1977 malignant neoplasms.

RESULTS

Table II summarizes the distribution by sex and race of 1977 malignant tumours accumulated over a period of 13 years, and diagnosed at autopsy and by histological examination. Of these tumours 580 were derived from Europeans, 1273 from Africans and 124 from the other races.

Amongst the European males, 303 malignant neoplasms were found. The skin accounted for 30·0 per cent of all tumours and thereafter, in order of frequency, the stomach for 8·9 per cent, the large intestine and rectum together for 8·9 per cent and malignancies of lymphoid tissue (8·9 per cent) and larynx and lung (9·5 per cent) (Table III). Amongst the European females, 23·8 per cent of all carcinomas occurred in the breast, 24·8 per cent in the cervix and the uterus and 15·1 per cent in the skin. That is to say, in females, 63·7 per cent of all cancers were obtained from the breast, uterus (including the cervix) and skin. The ratio of carcinoma of the body of the uterus to carcinoma of the cervix in European women was 1:4·6. Three Kaposi tumours were diagnosed in Europeans, two in males and one in a female. One chorionepithelioma, two gliomata of the brain, one glioma of the eye, three sarcomata of the connective tissue and bone and two lymphosarcomata occurred in Europeans under the age of 20 years. Breast carcinoma and carcinoma of the body of the uterus and skin cancer did not appear in European women in Lourenço Marques under the age of 20 years (Table II).

As far as the Africans are concerned, it is evident from Table II that of a total of 842 malignant neoplasms amongst males, $43 \cdot 1$ per cent were primary in the liver. Liver cancer, therefore, was at least three times as common as any other tumour. The skin (13.9 per cent), the lymphatic tumours (8.6 per cent) and the bladder (7.9 per cent) were next in order of frequency. Cancers of these four sites accounted for 73.6 per cent of all cancers in African males as compared with 40.5 per cent for the same sites in European males. Carcinoma of the stomach (1.0 per cent), of the oesophagus (0.4 per cent), colon (0.3 per cent), rectum (0.1 per cent) as well as carcinoma of the larynx (0.2 per cent), lung and bronchus (0.3 per cent) occurred less frequently in the African male than comparable tumours in the European male.

Amongst the African females, carcinoma of the cervix uteri (20.6 per cent), carcinoma of the liver (14.6 per cent), carcinoma of the skin (13.9 per cent) and carcinoma of the bladder (7.2 per cent) comprised 56.3 per cent of all cancers, as compared with 36.6 per cent for tumours in comparable sites in European females.

In the African female, the relative frequency ratio of carcinoma of the breast was 7.4 per cent as compared with 23.8 per cent in the European female. The ratio of carcinoma of the corpus uteri to carcinoma of the cervix uteri was 1:18 in African women as compared with 1:4.6 in European women. One case of Kaposi's sarcoma was found in an African female as compared with 22 in African males.

Table II.—Distribution of All Malignant Neoplasms by Site, Type and Age in Europeans and Africans from April 1944—December 31, 1957

No.	Age groups												
Int. Nom.	Site	Туре	Race	Sex 10	10- 20	20- 30	30- 40	40- 50	50- 60	Over 60	•	Grand Total Total Coloured	
140 .	Lip	. Ca.	. Eur	M 0 F 0 M 0 F 0	1 0 1 0	0 0 1 3	0 0 0 0	1 0 1 2	0 0 0 0	5 0 0 2	$\begin{array}{c} 1 \\ 0 \\ 0 \\ 0 \end{array}$	$\left.\begin{array}{c} 8 \\ 0 \\ 3 \\ 7 \end{array}\right\} \ 18$	
141 .	Tongue	Sarcoma		$\begin{array}{cccc} M. & . & 0 \\ F. & . & 0 \\ M. & . & 0 \\ F. & . & 0 \\ \end{array}$	0 0 0	0 0 1 0	0 0 0	1 0 0 0	2 0 3 0	2 0 0 0	0 0 0 0	$\left.\begin{array}{c}5\\0\\4\\0\end{array}\right\}\cdot \ 9 + 2$	
142.1 .	Salivary gland Parotid	. Ca.	. Eur Afr	F 0	0 0 0 0	1 0 0 0	0 0 1 1	0 0 0 1	0 0 0 2	0 0 0 1	0 0 0 0	$\left. egin{array}{c} 1 \\ 0 \\ 1 \\ 5 \end{array} ight\} 6 + 1$	
144 .	Mouth	. Ca.	. Eur	F 0	0 0 0 0	0 0 0 0	0 0 1 4	0 0 5 4	1 1 3 0	2 0 3 0	1 0 1	$\begin{pmatrix} 4 \\ 1 \\ 13 \\ 9 \end{pmatrix} 27 + 1$	
145A .	Tonsil	. Ca.		M 0 F 0 M 0 F 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 2 0	1 0 1 0	1 0 0 0	1 0 0 0	$\left. egin{array}{c} 3 \\ 0 \\ 3 \\ 0 \end{array} ight\} 6 + 2$	
146 .	Naso-pharynx	. Ca.		M 0 F 0 M 0 F 0	0 0 0 0	0 0 0	0 0 0 0	1 0 0 0	1 1 0 0	0 0 0 0	0 0 0 0	$\left.\begin{array}{c}2\\1\\0\\0\end{array}\right\} 3$	
150 .	Oesophagus	. Са.		M 0 F 0 M 0 F 0	0 0 1 0	0 0 1 0	0 0 0 0	0 1 1 0	1 0 0 0	1	0 0 0 0	$\left. egin{array}{c} 1 \\ 1 \\ 4 \\ 0 \end{array} ight\} 6 + 2$	
151 .	Stomach	. Ca.	Afr	M 0 F 0 M 0 F 0	0 0 0	0 0 1 0	2 1 0 0	9 6 2 0	6 5 2 0	1 4	0 0 0 0	$\left. egin{array}{c} 27 \\ 13 \\ 9 \\ 0 \end{array} ight\} \ 49 \ \ + \ \ 3$	
152C .	Small intestine	. Ca.	Afr	M 0 F 0 M 0 F 0	0 0 0 0	0 0 0 0	0 1 0 0	0 1 1 0	0 0 0 1	1 0	0 0 0 0	$\left. egin{array}{c} 2 \\ 3 \\ 1 \\ 1 \end{array} ight\} 7$	
153A .	Large intestine	. Ca.	Afr	M 0 F 0 M 0 F 0	1 1 0 0	0 0 0	1 1 1 0	1 1 2 0	5 1 0 0	2 0	0 0 0	$\begin{bmatrix} 17 \\ 6 \\ 3 \\ 0 \end{bmatrix} 26 + 5$	

TABLE II—cont.

No.													
Int. Nom.	. Site . Rectum	Type Ca.	Race . Eur. Afr.	F. . <u>M</u> .	1- 10 . 0 . 0 . 0	10- 20 0 0 0	20- 30 0 0 0	30- 40 0 0 0	40- 50 0 0 0	50- 60 2 1 1	Over 60 7 1 0	? 1 0 0	$ \begin{array}{c} \text{Grand} \\ \text{Total Total Coloured} \\ \begin{array}{c} 10 \\ 2 \\ 1 \\ 3 \end{array} $
155	. Liver	. Ca. Primary	. Eur. Afr.	. M. F. . M.		0	0 0 113 21	0 0 83 16	4 0 53 7	1 2 26 5	3 1 15 5	0 0 4 1	$ \begin{array}{c} 8 \\ 3 \\ 363 \\ 63 \end{array} \right\} 437 + 6 $
155C	. Gall bladder	. Ca.	. Eur.	F.	. 0	0 0 0 0	0 0 0 0	0 1 1 0	0 0 0 0	2 3 0 0	2 2 0 0	0 1 0 0	$\left. egin{array}{c} {\bf 4} \\ {\bf 7} \\ {\bf 1} \\ {\bf 0} \end{array} \right\} \ {f 12} \ \ + \ \ {f 2}$
157	. Pancreas	. Са.	. Eur. Afr.	\mathbf{F} .	. 0	0 0 0 0	0 0 0 0	0 0 3 0	1 0 3 0	1 0 1 0	0 0 1 1	1 0 0 0	$\left. \begin{array}{c} {\bf 3} \\ {\bf 0} \\ {\bf 8} \\ {\bf 1} \end{array} \right\} \ {\bf 12} \ \ + \ \ {\bf 2}$
158	. Abdominal cavity	. Са.	. Eur. Afr.	F.	. 0	0 0 0 0	0 0 1 1	0 0 0 1	0 0 0 0	2 1 1 0	0 2 1 1	0 0 0 0	$\begin{bmatrix} 2 \\ 3 \\ 3 \\ 3 \end{bmatrix} 11 + 1$
160A	. Nose	. Са.	. Eur.	F.	. 0	0 0 0	0 0 0 0	0 0 1 0	0 0 0 0	2 0 0 0	0 0 0 0	0 0 0 0	$\left. egin{array}{c} 2 \\ 0 \\ 1 \\ 0 \end{array} \right\} 3$
161	. Larynx	. Ca.	. Eur.	F. .	0	0 0 0 0	0 0 0 0	1 1 0 0	1 0 2 0	5 0 0 0	7 0 0 0	1 0 0 0	$\begin{bmatrix} 15 \\ 1 \\ 2 \\ 0 \end{bmatrix} 18 + 2$
162B 162C	. Lung . Bronchus	. Ca.	. Eur.	F. .	0	0 0 0 0	0 0 0 0	0 0 0 0	3 0 0 0	3 1 0 0	7 0 3 0	1 0 0 0	$\begin{bmatrix} 14 \\ 1 \\ 3 \\ 0 \end{bmatrix} 18 + 2$
170	. Breast	. Ca.	. Eur.	F	0	0 0 0 0	0 3 0 3	0 12 0 6	0 22 1 9	0 18 0 6	0 8 0 7	0 3 0 1	$ \left. \begin{array}{c} 0 \\ 66 \\ 1 \\ 32 \end{array} \right\} 99 + 12 $
17]	. Cervix uteri	. Са.	. Eur. Afr.	F. .	0	0 0 0 0	0 0 0 9	0 11 0 18	0 20 0 28	$\begin{array}{c} 0 \\ 14 \\ 0 \\ 20 \end{array}$	0 9 0 10	0 1 0 4	$\begin{bmatrix} 0 \\ 55 \\ 0 \\ 89 \end{bmatrix} 144 + 21$
172	. Corpus uteri	. Ca., 21 Sarcoma, 2	. Eur. · Afr.	F	0 0 0 0	0 0 0 0	0 2 0 0	0 1 0 1	0 1 0 1	0 4 0 1	0 5 0	0 1 0 1	$\begin{bmatrix} 0 \\ 14 \\ 0 \\ 4 \end{bmatrix} 18 + 5$
173	. Uterus	. Chorion- epithelioma	. Eur.	F. .	0 0 0 0	0 1 0 0	0 0 0 2	0 6 0 0	0 2 0 0	0 0 0 0		0 1 0 0	$\begin{bmatrix} 0 \\ 10 \\ 0 \\ 2 \end{bmatrix} 12 + 4$

TABLE II—cont.

N-									A	ge g	roup	s			•		
No. Int.							ī-	10-	20-	30-	40-	50-	Over	$\overline{}$	Grand	l	
Nom.	Site	$\mathbf{T}\mathbf{y}$	-	Race	Sez		10	20	3 0	4 0	50	60	60	?	Total Total	Co	loured
175A .	Ovary	. Ca	a.	. Eur.	. M. F.		0	0	$egin{matrix} 0 \\ 2 \\ \end{bmatrix}$	0 2	0	0 5	0	0	$\begin{bmatrix} 0 \\ 9 \end{bmatrix}$ 14		
				Afr.	. M.		0	0	0	0	0	0	0	0	0		
					F.	•	0	1	0	2	0	1	1	0	5		
176 .	Vagina	. Ca	a.	. Eur.			0	0	0	0	0	0	0	0	0)		
				Afr.	F. M.		0	0	0	0	2 0	2 0	$egin{matrix} 1 \\ 0 \end{bmatrix}$	1 0	$\begin{pmatrix} 6 \\ 0 \end{pmatrix}$ 30		
				AII.	F.		Ö	ì	4	3	7	4	5	Ö	24		
177 .	Prostate	. Ca	a.	. Eur.	. м.		0	0	0	0	0	6	4	0	10)		
					\mathbf{F} .		0	0	0	0	0	0	0	0	0 > 20	+	2
				Afr.	. M. F.		0	0	0	1 0	1 0	2 0	6 0	0	$\begin{bmatrix} 10 \\ 0 \end{bmatrix}$	•	
178 .	Testes	Van	ious	. Eur.	. м.		0	0	1	1	1	ı	0	0	4.5		
170 .	restes	. var neopl		. Eur.	. M.	•	0	0	0	0	0	0	Ö	ŏ	$\begin{bmatrix} 4 \\ 0 \\ 1 \end{bmatrix}$		
		-		Afr.	. M. F.		0	0	0	1 0	0	0	0	0	$\begin{bmatrix} 1 \\ 0 \end{bmatrix}$		
						-	-	-				_	-		- ,		
179A .	Scrotum	. Ca	a.	. Eur.	. M. F.	•	0	0	0	1 0	0	0	0	0	$\begin{bmatrix} 1 \\ 0 \end{bmatrix}$		
				Afr.	. M.		0	0	0	ì	0	1	0	0	2 > 3		
					F.	•	0	0	0	0	0	0	0	0	0)		
179B .	Penis	. Ca	a.	. Eur.			0	0	0	0	0	1	1	0	2		
				Afr.	F. M.	•	0	0 1	0 1	0 5	$0 \\ 12$	0 5	0 3	0 2	$\begin{bmatrix} 0 \\ 29 \end{bmatrix} 31$	+	4
					F.		0	0	0	0	0 ·	0	0	0	0		
180 .	Kidney	. Var	ious	. Eur.	. M.		0	0	0	0	1	2	0	0	3]		
		neopl	asms	Afr.	F.		$\frac{0}{1}$	0 1	0 1	0	1 0	1 0	0	0	$\begin{pmatrix} 2 \\ 4 \end{pmatrix}$ 12	+	2
				Air.	F.		ì	0.	0	2	0	Ö	Ö	ŏ	3		
181A .	Bladder	. Са		. Eur.	. м.		0	0	0	0	1	0	2	0	3)		
			•		F.		0	0	Ō	1	0	0	1	0	2 102	+	7
				Afr.	. M. F.	•	0	0	8 2	16 8	23 8	9 6	9 6	2 1	$\begin{bmatrix} 67 \\ 31 \end{bmatrix}$	٠	•
100	Skin	36.1		177	3.5		•										
190 .	okin	. Mela blast		. Eur.	F.		0	0	0	0	$0 \\ 1$	0	$0 \\ 1$	0	$\begin{bmatrix} 0 \\ 2 \end{bmatrix}$		
				Afr.	. M.		0	0	2 1	$\frac{1}{2}$	7 1	2 0	3 4	1 2	$\begin{array}{c c} 16 & 28 \\ 10 & & \end{array}$		
	*					•	U	U		_		-	_	_	10		
191A . 191B	"	. Basal o	cell ca.	. Eur.	. M. F.	٠.	0	0	3 0	${f 5}$	20 6	$\frac{23}{13}$	$\begin{array}{c} 32 \\ 15 \end{array}$	6 3	89		
1011		Ouite	ı ca.	Afr.	. M.	:	1	6	12	15	26	12	4	3	79 \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	+	9
					F.	•	0	2	7	9	15	3	13	0	4 9 J		
191D .	,,	. Kap		. Eur.			0	0	0	2	0	0	0	0	2)		
		tum	our	Afr.	F. M.	:	0	$egin{matrix} 0 \\ 2 \\ \end{bmatrix}$	0 2	0 3	0 5	1 7	$egin{matrix} 0 \\ 2 \end{matrix}$	0 1	$\begin{array}{c c}1\\22\end{array}$ 26		
					F.	•	0	0	0	0	0	0	ī	0	ī		
192A .	$\mathbf{E}\mathbf{y}\mathbf{e}$. Glio	ma	. Eur.		•	0	0	0	0	0	0	0	0	0]		
				Afr.	F. . M.	:	1 3	0	0	0	0	0	1 0	0	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		
				4211.	F.	:	2	Ö	Ö	0	0	0	0	0	$\begin{bmatrix} 3 \\ 2 \end{bmatrix}$		

Age groups

TABLE II—cont.

No.					Ago gi	oups		
Int. Nom.	Site	\mathbf{Type}	Race Sex	1- 10- 10 20	20- 30- 30 40	40- 50 Over 50 60 60		and otal Coloured
192C	. Еуе	. Various neoplasms	. Eur M F Afr M F	0 1 0 0 1 2 3 0	0 0 0 0 3 5 3 4	$\begin{array}{ccccc} 1 & 0 & 0 \\ 0 & 0 & 0 \\ 2 & 1 & 0 \\ 4 & 1 & 2 \end{array}$	$ \left.\begin{array}{ccc} 1 & 3 \\ 0 & 0 \\ 0 & 14 \\ 0 & 17 \end{array}\right\} 3$	34 + 1
19 3A	. Brain	. Glioma	Eur M F Afr M F	2 0 0 0 2 4 1 0	0 0 0 0 3 3 0 0	$\begin{array}{ccccc} 2 & 1 & 1 \\ 0 & 0 & 0 \\ 2 & 0 & 0 \\ 1 & 0 & 0 \end{array}$	$\left.\begin{array}{ccc} 2 & 8 \\ 0 & 0 \\ 0 & 14 \\ 0 & 2 \end{array}\right\} \ 2$:4
194	. Thyroid gland	. Ca.	. Eur M F Afr M F	0 0 0 0 0 1 0 0	1 0 0 0 2 0 2 1	$\begin{array}{cccc} 0 & 0 & 0 \\ 1 & 0 & 0 \\ 0 & 0 & 0 \\ 2 & 1 & 0 \end{array}$	$\left. \begin{array}{ccc} 0 & & 1 \\ 0 & & 1 \\ 0 & & 3 \\ 0 & & 6 \end{array} \right\} \ 1$	1 + 1
196	. Jawbone	. Various neoplasms	. Eur M . F Afr M F	0 0 0 0 0 6 0 1	$egin{array}{cccc} 2 & 0 & 0 & 0 \\ 0 & 0 & 1 & 3 & 2 & 4 & \end{array}$	$\begin{array}{cccc} 1 & 0 & 0 \\ 0 & 0 & 0 \\ 1 & 0 & 1 \\ 1 & 0 & 0 \end{array}$	$\left. \begin{array}{ccc} 0 & 3 \\ 1 & 1 \\ 0 & 12 \\ 0 & 8 \end{array} \right\} 2$	4
196C	. Other bones	. Sarcoma	. Eur M F Afr M F	$egin{array}{ccc} 0 & 1 \\ 0 & 0 \\ 1 & 2 \\ 0 & 0 \\ \end{array}$	$egin{array}{ccc} 0 & 0 & 0 \ 0 & 0 \ 3 & 2 \ 1 & 1 \ \end{array}$	$\begin{array}{cccc} 0 & 1 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 1 \end{array}$	$\left. egin{array}{ccc} 0 & & 2 \\ 0 & & 0 \\ 0 & & 8 \\ 0 & & 3 \end{array} ight\} 1$	3 + 2
197	. Connective tissue	. Sarcoma	. Eur M F Afr M F	$egin{array}{cccc} 1 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 &$	1 3 2 4 9 9 2 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \left. \begin{array}{ccc} 1 & 10 \\ 0 & 13 \\ 3 & 46 \\ 0 & 15 \end{array} \right\} 8 $	4 + 6
198	. Lymph nodes	. Secondary : Ca. Sarcoma		0 0 0 0 0 2 0 0	$egin{array}{ccc} 0 & 1 \\ 0 & 1 \\ 5 & 1 \\ 0 & 1 \\ \end{array}$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\left.\begin{array}{ccc} 1 & 10 \\ 0 & 3 \\ 1 & 15 \\ 0 & 3 \end{array}\right\} 3$	1 + 2
200.0	. Various sites	. Reticulum cell sarcoma	Eur M F Afr M F	0 0 1 0 3 0 3 0	0 0 0 2 0 0 1 0	$\begin{array}{cccc} 0 & 1 & 1 \\ 0 & 0 & 0 \\ 1 & 0 & 0 \\ 0 & 0 & 0 \end{array}$	$\left. \begin{array}{ccc} 0 & & 2 \\ 0 & & 3 \\ 1 & & 5 \\ 0 & & 4 \end{array} \right\} \ 1$	4 + 2
200.1	. Ditto	. Lympho- sarcoma	. Eur M F Afr M F	2 0 0 0 10 4 6 3	$egin{array}{cccc} 0 & 1 & & & & & & & & & & & & & & & & &$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\left.\begin{array}{ccc} 0 & 9 \\ 0 & 0 \\ 0 & 26 \\ 0 & 17 \end{array}\right\} \ 5$	2 + 3
201	. Lymph nodes	. Hodgkin's disease	. Eur M F Afr M F	$\begin{array}{ccc} 0 & 1 \\ 0 & 1 \\ 0 & 7 \\ 0 & 1 \end{array}$	4 1 3 1 9 9 1 1	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\left.\begin{array}{ccc} 2 & 12 \\ 0 & 6 \\ 0 & 34 \\ 0 & 8 \end{array}\right\} \ 66$	0 + 6
203 204B 204E	. Various sites	. Myeloma Lymphatic and myeloid leukaemia	. Eur M F Afr M F	$egin{array}{ccc} 0 & 0 & 0 \\ 0 & 0 & 1 \\ 1 & 1 \\ 0 & 0 & \end{array}$	$egin{array}{cccc} 0 & 1 & \\ 0 & 0 & \\ 0 & 5 & \\ 0 & 1 & \\ \end{array}$	$\begin{array}{cccc} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 1 & 0 & 0 \\ 1 & 1 & 1 \end{array}$	$ \left. \begin{array}{ccc} 0 & & 1 \\ 0 & & 0 \\ 0 & & 8 \\ 0 & & 4 \end{array} \right\} \ 1 $	3
		Totals	F Eur.—	2 3 28 115 1	12 48 6 82 176 17 67 92 9	68 76 56 1 74 87 61 1	20 303 12 277 19 842 11 431	

Table III.—Distribution by Site, Type and Sex, of all Malignant Neoplasms in Europeans, Africans and Coloureds* from April 1944—December 31, 1957

		·				•				·				Per- centage
No. Int.				Eur	opea	n		Afı	rican		Color	ured		of all neo-
Nom.	Site	\mathbf{Type}	M.	%	F.	%	M.	%	F.	%	M.	F.	Total	plasms
140	Lip	Ca.	8	$2 \cdot 64$	0	0	3	$0 \cdot 36$	7	$1 \cdot 62$	0	0	18	$0 \cdot 91$
141	\mathbf{Tongue}	,,	5	1.65	0	0	4	0.47	0	0	l	0,5	11	0.56
	a	Sarcoma	0	0	0	0	0	0	0	0	0	ijſ	• • •	0 00
142.1	Salivary	Ca.	1	0.33	0	0	0	0	5	1.16	l	0)	8	$0 \cdot 40$
144	gland parotid Mouth	Sarcoma Ca.	0 4	$0 \\ 1 \cdot 32$	0	$0 \\ 0 \cdot 36$	197	0.12	0 8ე	0	0 1	$\begin{cases} 0 \\ 0 \end{cases}$		
177	Modell	Sarcoma	0	0	0	0	$\begin{pmatrix} 12 \\ 1 \end{pmatrix}$	> 1·54	i }	2 · 1	0	0 >	28	$1 \cdot 42$
145A	Tonsil	Ca.	3	0.99	ŏ	ŏ	$\hat{3}^{j}$	0.36	ō	0	$\overset{\circ}{2}$	ŏſ	8	0.40
146	Nasopharynx	,,	2	0.66	1	$0 \cdot 36$	0	0	0	0	0	0	3	$0 \cdot 15$
150	Oesophagus	,,	1	$0 \cdot 33$	1	$0 \cdot 36$	4	$0 \cdot 47$	0	0	2	0	8	$0 \cdot 40$
151	Stomach	,,	27	8.91	13	4.7	9	1.06	0	0	2	l	52	$2 \cdot 63$
152C	Small	, .	2	0.66	3	1.08	1	0.12	1	$0 \cdot 23$	0	0	7	$0 \cdot 35$
153A	instestine Large		15 \		5	١	3	0.36	0	0	3	1)		
10011	intestine	,, Carcinoid	2	· 5·61	i	2 · 17	0	0	ő	Ö	0	i >	31	$1\cdot 57$
154	Rectum	Ca.	10	3 · 31	$\hat{2}$	0.72	ì	0.12	3	0.70	ì	3	20	$1 \cdot 02$
155A	Liver	Ca. (Primary)	8	$2 \cdot 64$	3	1.09	363	43.11	63	$14 \cdot 62$	5	ì	443	$22 \cdot 42$
155C	Gall bladder	Ca.	4	$1 \cdot 32$	7	$2 \cdot 51$	1	0.12	0	0	l	1	14	$0 \cdot 70$
157	Pancreas	,,	3	0.99	0	0	8	0.95	1	$0 \cdot 23$	1	1	14	$0 \cdot 70$
158	Abdominal	,,	2	0.66	3	$1 \cdot 09$	3	$0 \cdot 36$	3	$0 \cdot 70$	0	1	12	0.61
160A	cavity Nose		2	0.66	0	0	1	0.12	0	0	0	0	3	0.15
161	Larynx	,,	$1\overline{5}$	4.95	ì	0.36	$\overset{1}{2}$	$0.12 \\ 0.24$	0	0	2	0	20	1.02
162C	Lung	,,	14	4.62	i	0.36	$\tilde{3}$	0.36	ŏ	ŏ	ĩ	ì	20	$1.02 \\ 1.02$
	Bronchus	,,			_		ŭ	• ••		· ·	-	-		1 02
170	Breast	,,	0	0	66	$23 \cdot 83$	1	$0 \cdot 12$	32	$7 \cdot 42$	0	12	111	$5 \cdot 61$
171	Cervix uteri	,,	0	0	55	$19 \cdot 87$	0	0	89	$20 \cdot 65$	0	21	165	$8 \cdot 36$
172	Corpus uteri	g."	0	0	13)	5.05	0	0	4)	0.93	0	3 }	22	1.11
173	Uterus	Sarc. Chorion-	0	0	1 10	3.6	0	0	$egin{pmatrix} 0 \ 2 \end{bmatrix}$		0	1 }		
170	C tel us	epithelioma	U	U	10	9.0	U	U	Z	0.46	0	4	16	0.81
175A	Ovary	Ca.	0	0	9	$3 \cdot 25$	0	0	5	1.16	0	0	14	0.70
176	Vagina	,,	0	0	6	$2 \cdot 17$	Ō	Ō	24	5.57	ŏ	ŏ	30	1.52
177	Prostate	,,	10	$3 \cdot 31$	0	0	10	$1 \cdot 2$	0	0	2	0	22	$1 \cdot 11$
178	Testes	Seminoma	2	1.32	0	0	1	0.12	0	0	0	0 \	5	$0 \cdot 25$
179A	Q4	Sarcoma	2 }		0	0	0	0	0	0	0	0 5		
179A 179B	Scrotum Penis	Ca.	1 2	$0.33 \\ 0.66$	0	0	$\frac{2}{29}$	0.24	0	0	0	0	3	0.15
180	Kidney	Various	3	0.99	2	0.72	29 4	$3 \cdot 44 \\ 0 \cdot 47$	0 3	$0 \\ 0 \cdot 70$	4 0	$egin{matrix} 0 \\ 2 \\ \end{bmatrix}$	35 14	$1 \cdot 77$ $0 \cdot 70$
	111anoy	neoplasms		0 00		0 12	*	0 11	•	0.10	U	2	14	0.70
181A	$\mathbf{Bladder}$	Ca.	3	0.99	2	$0 \cdot 72$	67	$7 \cdot 96$	31	$7 \cdot 19$	7	0	110	$5 \cdot 56$
190	\mathbf{Skin}	Melano-	0	0	2	$0 \cdot 72$	16	$1 \cdot 9$	10	$2 \cdot 3$	0	Ó	28	$1 \cdot 42$
		blastoma												
191A	,,	Basal cell Ca.	73	$24 \cdot 08$	32	11.55	14	1.66	15	$3 \cdot 48$	5	1	140	$7 \cdot 09$
191D 191D	,,	Other ca.	$\begin{array}{c} 16 \\ 2 \end{array}$	$5 \cdot 27 \\ 0 \cdot 66$	7	2.51	65	$7 \cdot 72$	34	7.89	2	1	125	$6 \cdot 33$
1911	,,	Kaposi's tumour	2,	0.00	1	$0 \cdot 36$	22	$2 \cdot 61$	1	$0 \cdot 23$	0	0	26	$1 \cdot 32$
192A	Eye	Glioma	0	0	2	0.72	3	0.36	2	0.46	0	0	7	$0 \cdot 35$
192C	,,	Various	3	0.99	ō	0	14	1.66	17	3.94	ŏ	ĭ	35	1.77
		neoplasms												
193A	Brain	Ditto	8	2.64	0	0	14	1.66	2	0.46	0	0	24	$1 \cdot 21$
194	Thyroid	Ca.	1	0.33	1	$0 \cdot 36$	3	$0 \cdot 36$	6	$1 \cdot 4$	1	0	12	0.61
196	gland Jawbone	Adamantinoma	1)		01		57		43		Δ	۵.		
100	o a w DOITA	Sarcoma	2	0.99	1 (0.36	$\left\{\begin{array}{c}5\\7\end{array}\right\}$	1.43	$\left\{\begin{array}{c} 4\\4 \end{array}\right\}$	$1 \cdot 86$	0	$\left\{ \begin{smallmatrix} 0 \\ 0 \end{smallmatrix} \right\}$	24	1.21
196C	Other bones	Sarcoma	$\frac{2}{2}$	0.66	ō	0	8	0.95	3	0.70	2	0	15	0.76
197	Connective	••	10	$3 \cdot 31$	13	$4 \cdot 7$	46	$5 \cdot 46$	15	3.48	$ar{f 2}$	4	90	4.55
	tissue													

Т	ABLE	TTT	[cont.
			— (A)'III.

No. Int.				Eur	ropean			Af	rican		Color	ıred		Per- centage of all neo-
Nom.	Site	\mathbf{Type}	M.	%	F.	%	M.	%	F.	%	M.	Ė.	Total	plasms
198	Lymph nodes	Secondary ca. Sarcoma	9) 1)	3 ⋅31	$\binom{2}{1}$	1.09	14 ` 1	1.78	3 0	0·70 0	1 0	$\left\{ \begin{array}{c} 1 \\ 0 \end{array} \right\}$	33	1.67
200.0	Various sites	Reticulum cell sarcoma	2	0.66	3	1.09	5	0.59	4	0.93	1	1	16	0.81
200.1	Ditto	Lympho- sarcoma	9	$2 \cdot 97$	0	0	26	3.08	17	3.94	3	0	55	$2 \cdot 78$
201	Lymph nodes	Hodgkin's disease	12	$3 \cdot 95$	6	$2 \cdot 17$	34	4.04	8	1.86	3	3	66	$3 \cdot 34$
203	Bones	Myeloma	1	0.33	0	0	2	$0 \cdot 24$	1	$0 \cdot 23$	0	0	4	$0 \cdot 20$
204B	Blood	Lymphatic leukaemia	0	0	0	Ŏ	ō	0	3	0.70	1	0	4	$0 \cdot 20$
204A	"	Myeloid leukaemia	0	0	0	0	6	0.71	0	0	0	0	6	0.30
		Totals	303	100	277 1	.00	842	100	431	100	57	67	1977	100

^{*} As a total of only 124 neoplasms were observed amongst Coloured peoples, the percentage frequency of these tumours has not been included.

From this analysis, several trends in the tumour ratio frequency can be recognized in Lourenço Marques, namely,

- 1. A predilection of cancer for the liver in African males and females as compared with the European;
- 2. carcinoma of the cervix uteri is relatively more frequent than carcinoma of the corpus uteri in African as compared with European women;
- 3. breast carcinoma appears to be less common in African than in European women;
- 4. skin cancer in the European male is more common than in the African male although the types of skin tumours developed by the two races are not the same;
 - 5. carcinoma of the lung, oesophagus, stomach, large bowel and rectum are relatively uncommon in the African as compared with the European (Table II).

Data for the Indian, Chinese and Coloured groups are too limited for analysis and are merely included in Table II as additional information on tumour frequency.

Preliminary information from our rates survey discloses that only a small percentage of Africans live beyond the age of 65 years. The age structure of the population may influence profoundly the site incidence of cancer. Nevertheless, one fact is outstanding, namely, that as far as liver cancer is concerned, it occurs with unusual frequency under the age of 40 years (Table VI). Of a total of 363 cases of primary carcinoma of the liver in males, no less than 182 occurred under the age of 30 years while in females, 29 of 63 were present under the age of 30 years. It may well be that when corrected for the age distribution of the population, carcinoma of the liver may increase still further with age. But, at present, the early development of liver carcinoma in young people cannot be disputed.

TABLE IV.—Primary	Carcinoma d	of the Liver	, by	Race,	Sex and	Age
-------------------	-------------	--------------	------	-------	---------	-----

No. Age groups Int.																
Nom.	Site	\mathbf{Type}	Race	8	Sex	•	1–10	10-20	20-30	30-40	40-50	50-60	Over 60	?	١.	Total
155a .	Liver .	Carcinoma (Primary)	European		M. F.		0	0	0	0	4 0	1 2	3 1	0		8 3
			African		М. F.			67 7	113 21	83 16	5 3 7	26 5	15 5	4 1	:	363 63
			Coloured		М. F.		1 0	0 1	0	2 0	0	1 0	1 0	0		5 1
			To	tal			<u> </u>	— 75	134	101	64	35	 25	5	•	443

The frequency ratio of malignant neoplasms in Africans since the establishment of the Cancer Survey Unit (Table VII)

As already mentioned above, a special cancer survey was initiated in May 1956. As a result, interest in the cancer problem grew rapidly amongst the doctors in the city of Lourenço Marques and in the hospital. This did not affect to any extent the number of specimens sent to the laboratory from outlying regions but it did increase the number of histological examinations of material obtained at operation in the hospital. The number of autopsies increased to over 80 per cent of all patients dying in the hospital.

During the past 19 months, 210 malignant neoplasms found in Africans were diagnosed histologically. In the male African, the liver accounted for 45 per cent, the skin for 11·4 per cent and the urinary bladder for 8·2 per cent of all cancers. That is to say, 64·6 per cent of all tumours occurred in these three sites. In females, 18·1 per cent of carcinomata were observed in the cervix uteri, 11·3 per cent in the liver, 11·36 per cent in the bladder and 11·5 per cent in the skin. These tumours represented 52 per cent of all neoplasms in African women. Up to the present, 16 carcinomata of the cervix uteri have been detected and not a single carcinoma of the body of the uterus. Carcinoma of the oesophagus and of the lung and bronchus were uncommon. Only 2 cases occurred in 210 malignant growths in both sexes. Sarcoma of the jaw and other regions of the skeleton yielded 9·8 per cent of tumours, while primary malignant neoplasms of the lymphoid tissues were found in 9·0 per cent of cases. The frequency of carcinoma of the pancreas remained low (0·82 per cent).

A comparison of the data collected over the 19-month period with that accumulated over the entire previous 13 years reveals that while the frequency ratios were not always identical, the general trend in site incidence remained the same. A relatively small series of 210 neoplasms collected over a period of 19 months, therefore, can yield useful suggestive information about the frequency ratio of the more commonly occurring tumours.

Cancer rates in the population of Lourenço Marques

The cancer rates survey was also initiated 19 months ago and relates to the African population numbering approximately 100,000. One hundred and sixty-one tumours have been studied. As previously mentioned, unless confirmed histolo-

gically, all malignant cases diagnosed radiologically and clinically were excluded from the above analysis.

If the maternity cases are also excluded, four times as many males were admitted to hospital as females, indicating that some sociological factor may have determined the male preference for seeking medical attention and admission to

Table V.—Ratio Survey of Malignant Neoplasms in Africans of Lourenço Marques from May 1956–December 1957

No.							Mal	е		· F	ema	le		m-4-1		D.,,
Int.						Actu	 اه	_		Actu	 al			Total M.		Per- centage
Nom.		Site		\mathbf{Type}		numb		%		numb		%		and F.		M. and F.
141				• •												
141 142.1	•	Tongue	٠	Ca.		1		0.82	•	0	(•	. 1	٠	0.48
142.1	٠	Salivary gland	•	,,	•	. 0		0	•	1	-	l·14	•	. 1	٠	$0 \cdot 48$
144		Mouth				. 1		0 · 82	•	1	,	l · 14		. 2		0.95
153A	•	Large	•	***	•	. 1 . 1		0.82	•	0	Ċ		•	1.	•	0.48
10011	•	intestine	•	,,	•	. 1		0.02	•	U	,	,	•	1.	•	0.40
155A		Liver				. 55	4	5 · 06		10	11	l · 36		65		$30 \cdot 96$
157		Pancreas	•	"		. 1		0.82	•	ő	- (l	•	0.48
158		Abdominal		,,		. 0		0	Ċ	$\check{2}$		2 · 27		$ar{2}$		0.95
		cavity	•	,,		. 0		0	•	-	•			_	•	0 00
161		Larynx		,,		. 2		1 · 64		0	()		. 2		0.95
162C		Lung and		,,		. 2		1 · 64		Õ	(2		0.95
		bronchus		,,							•					
170		Breast		,,		. 0	(0		10	11	.36		10		4.77
171		Cervix uteri		,,		. 0	(0		16	18	3 · 18		16		$7 \cdot 62$
175A		Ovary		Sarcoma		. 0	(0		1]	1.14		l		0.48
176		Vagina		Ca.		. 0	(0		3	3	3.41		3		$1 \cdot 43$
177		Prostate		,,		. 1	(0.82		0	()		1		0.48
179B		Penis		,,		. 1	(0.82		0	()		1		0.48
180		\mathbf{Kidney}		,,		. 1	(0.82		0	()	ો	2		0.95
				Sarcoma		. 0	(0		1]	$1 \cdot 14$	ſ	_	•	0.95
181		${f Bladder}$		Ca.		. 10		$8 \cdot 2$	٠.	10		· 36	٠.	20		$9 \cdot 52$
190	•	Skin	•	Malignant melanoma	•	. 1	(0 · 82	•	1]	1 • 14	•	2	•	0.95
191A		,,	•	Basal cell ca.		. 4	:	$3 \cdot 28$		3	3	3·41		7		$3 \cdot 33$
191B	•	,,	•	Miscellaneous		. 6	4	$4 \cdot 92$		6	6	3 · 80		12		$5 \cdot 71$
				ca.												
191D	٠	 "	•	Kaposis		. 3		2.40	٠	0	0		٠.	3	•	$1 \cdot 43$
192C	•	$\mathbf{E}\mathbf{y}\mathbf{e}$	٠	Ca.	•	. 1)·82	•	2		2.27	Ţ	5		$2 \cdot 38$
1004		ъ.		Sarcoma	٠	. 1)·82	٠	1		· 14	J		•	
193A	•	Brain	•	Glioma	•	. 3	_	2.46	٠	0	C		•	3	•	$1 \cdot 43$
194	•	Thyroid gland	•	Ca.	٠	. 0)	•	2		2.27		2	•	0.95
196	•	Jawbone	•	Sarcoma	٠	. 8		3.56	٠	7		• 95	•	15	•	$7 \cdot 14$
196C	•	Other bones	•	,,	•	4		3 · 28	٠	1		·14		5	•	$2 \cdot 38$
197	•	Connective tissue	•	**	•	1)·82	•	3	3	•41	•	4	•	1.90
198	٠	Lymph nodes	•	Secondary ca.		2		64		0	0			2		$0 \cdot 95$
200.0	•	Various sites	٠	Reticulo- endothelial	•	2]	l · 64	•	2	2	2.27	•	4	•	1.90
200.1				sarcoma												
200.1	٠	**	•	Lympho-	•	4	3	$3 \cdot 28$	٠	1	1	· 14	٠	5	٠	$2 \cdot 38$
201		Lymph nodes		sarcoma Hodgkin's disease		3	2	2 · 46		1	1	·14		4		1.9
203		Bones		Myeloma		0	()		1	1	· 14		1		0.48
204B	:	Blood		Lymphatic	•	ĭ	_)) · 82	•	ì		.14	•	$\overset{1}{2}$	•	0.48
_			-	leukaemia	•	•	•	. 52	•	•	•		•	~	•	0 00
204E		,,	•	Myeloid leukaemia		2]	•64	•	1	1	· 14		3	•	1 · 43
				Total .		122	100			88	100			210	. 1	00

hospital. While the data collected during the first 19 months of our rates survey in a relatively small population can only afford an indication of the trends to be expected, nevertheless, even at this early stage, it is evident that the frequency of even the common tumours is further emphasized (Table VI). Thus, of 110 malignant neoplasms in males, 71 (64.54 per cent) were primary in the liver and of 51 malignant neoplasms in females, 13 (25.5 per cent) were primary in the liver. The bladder accounted for 8.18 per cent of tumours, and the skin for 7.27 per cent in males, these sites together with the liver accounting for 71.81 per cent of all malignant neoplasms. Again, the low frequency of lung carcinoma is noteworthy. However, almost one-third of all cancers in women were primary in the cervix uteri.

In general, the first 19 months of the intensive rates survey confirmed the trend observed in the cancer frequency ratios in all the material obtained in the past 13 years. As the survey progresses, it may well be that the frequency ratio of liver cancer will decline a little but, at present, there can be little doubt that amongst males, the liver is still the most frequent site of cancer. In females

Table VI.—Rates Survey of Malignant Neoplasms in Africans of Lourenço Marques from May 1956-December 1957

No. Int.						Actu	Mal nal	e		Act		male		Total M.		Per- centage
Nom.		Site		\mathbf{Type}		num	ber	%		num	be	r %		and F.		M. and F.
142.1	•	Salivary gland Parotid		Ca.		. 0		0	•	.]	l	1.96		. 1	•	0.62
144		\mathbf{Mouth}		,,		1		0.91		1		$1 \cdot 96$		2		$1 \cdot 24$
151		Stomach		,,		1		0.91		0)	0		1		0.62
153A	•	${f Large} \ {f intestine}$		"	•	1		0.91	٠	0)	0	•	1	•	$0 \cdot 62$
155A		Liver		,,		71	6	$4 \cdot 54$		13	;	$25 \cdot 5$		84		$52 \cdot 17$
146		Nasopharynx		,,		1		0.91		0)	0		1		0.62
170		Breast		•		0		0		1		1.96		1		0.62
171		Cervix uteri		,,		0		0		15	•	$29 \cdot 42$		15		$9 \cdot 31$
176		Vulva		. ,,		0		0		1		1.96		1		0.62
177		Prostate		,,		4		3 · 63		0)	0		4		$2 \cdot 48$
179B		Penis		,,		3		$2 \cdot 73$		0)	Ō		3		1.85
180		Kidney		Various		ĩ		0.91		ĩ		1.96		2		$1 \cdot 24$
		J		neoplasms		-			·	-			•	_	•	
181		$\mathbf{Bladder}$		Ča.		9		8.18		4		$7 \cdot 84$		13		$8 \cdot 07$
190		\mathbf{Skin}		Melano-		2		1.82		0)	0		2		$1 \cdot 24$
				blastoma												
191A,B		,,		Ca.		5		4.54		2	;	$3 \cdot 92$		7		$4 \cdot 44$
191D		,,		Kaposi		1		0.91		0		0		1		$0 \cdot 62$
192C		$\mathbf{E}\mathbf{y}\mathbf{e}$		Ca.		1		0.91		1	٦					
		•		Sarcoma		Ō		0		ī		$3 \cdot 92$	•	3	٠	$1 \cdot 85$
193A		Brain		Glioma	i	3		$2 \cdot 73$	i	2		$3 \cdot 92$		5		3 · 10
194		Thyroid gland		Ca.		ő		0 .0		$\bar{2}$		3.92	·	$\overset{\circ}{2}$	·	$1 \cdot 24$
196		Jawbone		Sarcoma		ĭ		o∙91		ō		0 02	J.	_	•	
			•	Adamantinoma		î		0.91	-	ŏ		ŏ	7	2	٠	$1 \cdot 24$
197	•	Connective tissue	•	Sarcoma		î		0.91	٠	2		$3 \cdot 92$	٠.	3		1 · 85
200.1		Various sites		Lymphosarcoma		1		0.91		1		1.96		2		$1 \cdot 24$
201		Lymph nodes		Hodgkin's		Ô)		ì		1.96	•	ĩ	:	0.62
		• •		disease									·	-	-	
204A	•	Blood	•	Myeloid leukaemia	•	2		1 · 82	٠	2		$3 \cdot 92$	•	4	•	$2 \cdot 48$
				Total .		110	100)		$\frac{-}{51}$	1	00		161		100

carcinoma of the cervix occurs more frequently than all other cancers, with cancer of the liver ranking next in order of importance and this despite the smaller number of women seeking hospital treatment. Both in males and females, cancer of the bladder is equally common, being second in order of frequency in males and third in the females. It is hoped that when the cancer rates survey is completed, it will be possible to know, with greater confidence whether carcinoma of the stomach, oesophagus, breast and lung are indeed lower in the African in Lourenço Marques, as the frequency ratio study seems to suggest. However, there is sufficient information to show that primary cancer of the liver is a particular problem in Lourenço Marques and justifies an intensive study into the aetological factors.

Comparison of cancer frequency ratios in Mozambique with that in other parts of Africa

With the exception of Kampala (1952–53) and Durban (1950–56), carcinoma of the liver in male Africans is the commonest tumour in all cancer surveys thus far reported from Johannesburg, Mozambique, Belgian Congo and Nigeria and reaches the highest frequency ratio in Lourenço Marques where liver carcinoma is twice as common as in Johannesburg and three times as common as in Kampala. It is of interest to note that Findlay (1940–45) reported 60 tumours in West African soldiers aged 18 to 40 years and of these 37 were primary cancer of the liver. Moreover, calculations made from the data presented by Elmes and Baldwin (1947) for Nigeria reveal a frequency ratio of 11·9 per cent for primary carcinoma of the liver.

The frequency ratio of carcinoma of the skin ranges from 11·2 to 16·3 per cent and is the commonest cancer in Kampala and Durban, second in order of frequency in Mozambique and Johannesburg (Higginson and Oettlé, 1958, personal communication) and third in the Stanleyville and in the data submitted by Berman (1935) for Johannesburg. Tumours of the bladder constitute between 4 and 8 per cent of all neoplasms in Mozambique, Johannesburg and Kampala but less than 1 per cent in Stanleyville. In Mozambique, bladder tumours are almost twice as frequent as in Johannesburg and Kampala.

The relatively high frequency ratio of carcinoma of the lung and bronchus in Johannesburg (7·7 per cent) (Higginson and Oettlé, 1958, personal communication) and in Durban (7·7 per cent) contrasts with the lower frequency of tumours of this organ in Kampala (1·95 per cent) and the rarity of this tumour in Mozambique (less than 1 per cent) and in Dakar (Camain, 1954). Similarly, the high frequency ratio of carcinoma of the rectum in Johannesburg (8.0 per cent) differs from the lower frequency in Kampala (2·3 per cent) and the still lower frequency ratio (less than 1 per cent) in Mozambique and Stanleyville. Apparently, tumours of the gastro-intestinal tract are more common in Johannesburg and Kampala than in Mozambique and Stanleyville. The frequency of carcinoma of the penis appears to be considerably higher in Kampala (10·0 per cent) than in any other African territory (1–4 per cent).

Females.—The high frequency ratio of carcinoma of the cervix is a feature of all reports from Africa with the exception of Dakar. In Nigeria, tumours of the uterus ranked second in order of frequency.

Skin tumours were found first in order of frequency in Durban and second in Johannesburg (12·1 per cent) and Stanleyville (13·2 per cent) and third in Mozambique (13·9 per cent in both sexes). In Kampala, skin tumours constituted only

8 per cent of all tumours and only 3 per cent in the figures published by Berman (1935) for Johannesburg.

The frequency ratio of liver carcinoma in African females was only slightly higher (14.6 per cent) than that of skin carcinoma (13.8 per cent) in Mozambique and was at least twice as high as the frequency ratio of liver carcinoma in Johannesburg (Higginson and Oettlé (6.0 per cent), Berman (5.0 per cent), Stanleyville (4.5 per cent) and Kampala (4.1 per cent). Carcinoma of the liver was consistently lower amongst females than in males in all the surveys presented in Tables VII and VIII.

The frequency ratio of breast tumours was variable. Whereas breast carcinoma constituted 7·4 and 9·0 per cent of all tumours in Mozambique and Kampala respectively, the percentage frequency was 11·3 and 12·0 per cent in Johannesburg (Higginson and Oettlé) and Stanleyville (Thijs, 1957) and 25·3 and 21·4 per cent in Johannesburg (Berman, 1935) and Nigeria respectively. Squamous cell carcinoma of the vagina was consistently higher in Mozambique (5·5 per cent) than elsewhere while tumours of the ovary appeared to be unusually high in Stanleyville (8·8 per cent) and in Kampala (11.5 per cent). Carcinoma of the gastrointestinal canal was unusual and involved mainly the stomach, the highest frequency ratio being reported in Johannesburg by Berman. Carcinoma of the rectum occurred in less than 1 per cent of tumours in all surveys, except in Kampala. Except in Durban (Wainwright and Roach, 1957) cancer of the lung and bronchus comprised 1·4 per cent or less of all tumours in females in all the surveys reported.

As in the African male, carcinoma of the bladder was high (7.9 per cent) in African females in Mozambique but was far less frequent in the other African territories. Camain (1954) from Dakar, reported on 1884 malignant neoplasms in Africans over an 11-year period. Unfortunately, he did not separate the sexes and therefore it is not possible to compare the Lourenço Marques tumours with those in Dakar. However, Camain does mention that two-thirds of the tumours were obtained from males and one-third from females. It would appear that the frequency ratio of primary liver cancer in Dakar is a little lower than in Lourenço Marques. Noteworthy in Dakar, as in Lourenço Marques, are the low frequency ratios of pancreatic, large bowel, lung and breast cancers. The ratio of cancer of the body to cancer of the cervix uteri in Dakar is as 1:5.7, which contrasts with the reported ratios from other parts of Africa.

From this comparative survey, whatever the limitations thereof, it is evident that in several territories south of the Sahara, primary liver cancer is the predominant malignant neoplasm in males, the only anomalous report being from Kampala. With the exception of Dakar and possibly also of Nigeria, carcinoma of the cervix uteri in females ranks first in importance amongst all neoplasms in African women. Both in males and in females, primary carcinoma of the liver, bladder and skin show a markedly higher frequency ratio in Mozambique than elsewhere in Africa. With the exception of Johannesburg and Kampala, carcinoma of the gastro-intestinal canal amongst Africans appears to be infrequent. At present, cancer of the lung and bronchus does not appear to be a problem of any significance amongst African females and, with the exception of Johannesburg, these tumours are also uncommon in African males.

The comparative analysis of the tumour frequency ratio reveals that primary liver cancer in males and cancer of the bladder in both sexes in Lourenço Marques

Table VII.—Order of Frequency of Malignant Neoplasms in African Males in Different Parts of the Continent of Africa ‡

		Louren	ço Marques		oj 11j	, , , , , , , , , , , , , , , , , , , ,	
1944–5 European†		(Prates) African		Johannesburg			
	_	٠		_	۸	1926-33 (Berman)	
Site	Total	ı %ં	Site	Total	%	Site Total	%
Skin	91	30·0	Liver .	. 363	43·1		31·0
Stomach	27	$8 \cdot 9$. 117	$13 \cdot 9$		14.7
Colon	17	$5 \cdot 6$	T 1 .	. 73	8.6		11.2
Larynx		$4 \cdot 9$. 67	$7 \cdot 9$	Bladder 5	$4 \cdot 3$
Lung and bron-		$4 \cdot 6$	Sarcoma .	. 46	$5 \cdot 5$	Lip 5	$\overline{4} \cdot \overline{3}$
chus			Penis .	. 29	$3 \cdot 4$	Penis 4	$3 \cdot 4$
Hodgkin's disease	12	$3 \cdot 9$	Kaposi's tumour		2.6	Pancreas 4	$3 \cdot 4$
Sarcoma	10	3.3	~ *	. 20	$\overline{2} \cdot \overline{3}$	Bones 4	$3 \cdot 4$
Lymph nodes .	10	3.3	-	. 17	$\overline{2} \cdot \overline{0}$	Prostate 3	2.6
Rectum		3.3	Lymph nodes:			Rectum 3	$\frac{5}{2} \cdot 6$
Prostate		$3 \cdot 3$	· / · · · · ·	. 15	1 · 7	Tongue 3	$\tilde{2} \cdot \tilde{6}$
Lip	_	$2 \cdot 6$. 14	1.6	Mouth 2	$\tilde{1} \cdot \tilde{7}$
Liver	_	$2 \cdot 6$	3.5	. 13	1.5	Nasal sinuses . 2	1.7
Brain	8	$2 \cdot 6$	T	. 10	$1 \cdot 2$	Lung and bron- 2	1.7
Tongue		$\tilde{1} \cdot \tilde{6}$	~	. 10	1.0	chus	1.1
Bones		1.6	Stomach .	. 9	1.0		1.7
Mouth	4	1.3					
		1.3				Lymph nodes . 2	$1 \cdot 7$
		1.3					
Testis	**	1.9					
		Johan	nnesburg				
	1953		inson and Oettlé)				
T		1953–55		Urhan	1953-55	Durban	
-		1000	`			1950–56 (Wainwright)	
Site	Total	۱ %	Site	Total		Site Total	0/
Liver	36	20.5		. 114	$22\overset{\circ}{\cdot}0$		$4 \cdot 1$
Skin		$14 \cdot 2$			10.2	Skin* 271 l Liver* 128	7.2
Rectum		8.0	Stomach	41	7.9		
Lung and bron-		7.4			7.7	Tunn and have 90	$6 \cdot 1$
chus	10	1.4	Lung and bron- chus	- 40	1.1		$4 \cdot 5$
Bones	11	$6 \cdot 3$	Hodgkin's disease	27	$5 \cdot 4$	chus*	9 9
-	8	4.5	~ ~ .		4.0	701 11 # #4	$3 \cdot 2$
	_	4.5		. Z1	4.0		$2 \cdot 8$
	6	$3 \cdot 4$	Lymph nodes:	90	9.0		$2 \cdot 8$
Sinuses	6	3·4 3·4	(secondary) .		3 · 8		$2 \cdot 5$
Leukaemia .		$3 \cdot 4$		18	3.4	Stomach* 44	$2 \cdot 2$
Lymphomata .			Mouth	18	$3 \cdot 4$	Naso-pharynx* . 44	$2 \cdot 2$
Kaposi's tumour		2.8	Bladder		$3 \cdot 2$		1.9
Salivary gland .		$2 \cdot 8$	Salivary gland .	15	2.8	Kaposi's tumour* 25	$1 \cdot 3$
Oesophagus .		$2 \cdot 3$	Brain	14	$2 \cdot 7$		
Stomach	4	$2 \cdot 3$	Skin		$2 \cdot 7$		
Kidney		$2 \cdot 3$	Kaposi's tumour.		$2 \cdot 1$		
Mouth	3	1.7	Pancreas		1.9		
103013	3	1.7	Penis and scrotum		$1 \cdot 7$		
Pancreas	2	1.1	Sinuses		$1 \cdot 7$		
Larynx	2	1.1	Larynx		$1 \cdot 5$		
Breast	2	1 · 1	Colon		1.3		
Eye	2	$1 \cdot 1$	Bones	6	1 · 1		
Penis and scrotum	2	1 · 1					
G. 1						Nigeria	
Stanleyvil			Kampal			1935-44	
1939–55 (Th			1952–53 (Da			(Elmes and Baldwin)	
Site	Total	_%_	Site	Total	%	Site Total	%
Reticulo-endothe-	190	16.3	Skin		$16 \cdot 3$	Liver 57 1	$1 \cdot 9$
lial tumours	• • • •		Liver		10 · 1		$4 \cdot 6$
	185	16.0	Penis		$10 \cdot 0$		$2 \cdot 7$
	179	15.5	Bladder		$4 \cdot 7$		$2 \cdot 1$
Kaposi's tumour.		13.3	Prostate	19	$4 \cdot 5$		$1 \cdot 7$
Sarcoma	68	$5 \cdot 9$	Stomach	19	$4 \cdot 5$		1.5
Penis	45	$3 \cdot 8$	Colon	15	$3 \cdot 5$		$1 \cdot 5$
Salivary gland .	33	$2 \cdot 9$	Eye	13	$3 \cdot 0$		$1 \cdot 0$
Stomach	19	1.6	Oesophagus .	11	$2 \cdot 6$		
Eye	19	1.6	Rectum	10	$2 \cdot 3$		
Breast	18	$1 \cdot 5$	Lung and bron-	8	$1 \cdot 9$		
Testis	12	1.0	chus				
Scrotum	12	$1 \cdot 0$	Pancreas	5	1.1		
+ T 1	41	1 0					

[†] Tumours less than 1·0 per cent are not included in this table.
† Europeans from Lourenço Marques included for comparison.
* Denotes both sexes.

Table VIII.—Order of Frequency of Malignant Neoplasms in African Females in Different Parts of the Continent of Africa ‡

					··· -J	у···· т		
	Lourenço Marques				A.C. to T. I. a. a. I. a.			
European†			African		rican	Johannesburg		
a					<u>ئى</u>	1926–33 (Berman)		
Site	Tota	1 %	Site	Tota	I %	Site Total %		
Breast	66	23.8		. 89	20.6	Cervix uteri . 27 27·3		
Cervix uteri .	55	19.8		. 63	14.6	Breast 25 25·3		
Skin	42	$15 \cdot 1$	Skin	. 60	$13 \cdot 9$	Corpus uteri . 15 $15 \cdot 2$		
Corpus uteri .		$5 \cdot 0$	${f Breast}$.	. 32	$7 \cdot 4$	Ovary $6 \cdot 6 \cdot 1$		
Stomach	13	$4 \cdot 7$	Bladder .	. 31	$7 \cdot 2$	Stomach 6 $6 \cdot 1$		
Sarcoma	13	$4 \cdot 7$	Lymphomata	. 25	$5 \cdot 8$	Liver $5 \cdot 5 \cdot 0$		
Chorion-epithe-	10	$3 \cdot 6$	Vagina .	. 24	$5 \cdot 5$	Skin 3 3·0		
lioma -			Eye	. 19	$4 \cdot 4$	Thyroid 3 $3 \cdot 0$		
Ovary	9	$3 \cdot 2$	~ *	. 15	$3 \cdot 4$	Lip 1 1·0		
Gall bladder .	7	$2 \cdot 5$	т.	. 11	$2 \cdot 5$	Salivary gland . 1 $1 \cdot 0$		
Vagina		$2 \cdot 1$	3.5 (3)	. 9	$2 \cdot 1$	Colon 1 1·0		
Colon	6	$\overline{2} \cdot \overline{1}$	Lip	. 7	1.6	Rectum 1 1.0		
Hodgkin's disease		$\overline{2} \cdot \overline{1}$	Thyroid .	. 6	1.4	Pancreas 1 1·0		
Small intestine .		$\tilde{1} \cdot \hat{0}$. 5	1.1	37		
Liver	3	1.0		. 5	1.1			
	3	1.0	Salivary gland	. 3	1.1			
Lymph nodes:	9	1.0				Kidney $1 \cdot 1 \cdot 0$		
(secondary) .	3	1.0				Lymph nodes . $1 \cdot 1 \cdot 0$		
		. .						
			nesburg					
		(Higgin	son and Oettlé)					
Rural, 195	3-55		Urban, 198	5355		Durban		
						1950-56 (Wainwright)		
Site	Total	۱ %	Site	Total	\ % ·	Site Total %		
Cervix uteri .	68	27.4		. 198	41·6	Cervix uteri . 374 19·2		
Skin	30	12.1	.	. 50	10.5	Skin* 271 14·1		
Breast	•	11.3	Liver .	. 25	$5 \cdot 2$	Liver* 128 7.2		
Liver	15	6.0		10	$\frac{3}{4} \cdot \tilde{0}$	Oesophagus* . 119 6·1		
Bones	14	5.6	~ .		3.5			
		4.8						
Salivary gland .			Leukaemia .	. 16	$3 \cdot 3$	Lung and bron- 89 4.5		
Corpus uteri .	9	3.6		. 16	$3 \cdot 3$	chus*		
Lymphomata .		3.6	Lymph nodes:			Bladder* 54 2.8		
Stomach	8	$3 \cdot 2$	(secondary)		$2 \cdot 7$	Mouth, tongue* . 50 2.5		
Sinuses	7	$2 \cdot 8$. 12	$2 \cdot 5$	Stomach* 44 $2 \cdot 2$		
Ovary		$2 \cdot 0$	Skin	. 12	${\bf 2\cdot 5}$	Nasopharynx* . 44 $2 \cdot 2$		
Bladder	5	$2 \cdot 0$	Salivary gland	. 12	$2 \cdot 5$	Intestine, colon* . 38 1.9		
Adamantinoma .	4	1.6	Large intestine	. 9	1.8	Ovary 30 1.5		
Kidney	4	1.6	Thyroid .	. 7	1 · 4	Vulva 25 1·3		
Eye	4	1.6	Lung and bron	- 7	$1 \cdot 4$	Kaposi's tumour * 25 1.3		
Pharynx	3	$1 \cdot 2$	chus	=				
Vulva	3	$\overline{1} \cdot \overline{2}$	Rectum .	. 6	$1 \cdot 2$			
Leukaemia .	3	$\hat{1} \cdot \hat{2}$	Chorion-	5	$1.\overline{0}$			
Beardenna .	U	1 4		v	1.0			
			e p i thelioma			Nimonia		
Stanlovvi	110		Vanama	1.		Nigeria		
Stanleyvi			Kampala 1952–53 (Davies)			1935–44		
1939–55 (TI	məsə	0/	1952–53 (D	avies)	0.4	(Elmes and Baldwin)		
Site	Total	1,%	Site	Total	,%_	Site Total %		
		17.9		. 58	18.5	Breast 77 21 · 4		
Skin	120	$13 \cdot 2$	Ovary		$11 \cdot 5$	Uterus 68 16·4		
	109	$12 \cdot 0$	Breast Skin		$9 \cdot 0$	Ovary $20 ext{ 5} \cdot 5$		
Ovary		$8 \cdot 8$	Skin	25	$8 \cdot 0$	Chorion-epithe- 9 2.5		
Reticulo-endo-	67	$7 \cdot 4$	Corpus uteri .	19	$6 \cdot 0$	lioma		
thelial tumours			Liver	13	$4 \cdot 1$	Vulva 7 1·9		
Sarcoma	44	$4 \cdot 9$	Colon	11	$3 \cdot 5$	Vagina 5 $1\cdot 4$		
Salivary gland .	41	$4 \cdot 5$	Oesophagus .	6	$2 \cdot 0$	Stomach 5 1.4		
Liver	41	$4 \cdot 5$	Rectum	6	$2 \cdot 0$			
Vulva	27	$\overline{2 \cdot 9}$	Eye	6	$\mathbf{\tilde{2}\cdot \tilde{0}}$			
Kaposi's tumour .	18	$\overline{1} \cdot \overline{9}$	Stomach	5	1.6			
Stomach	14	1.5	Vagina		$1 \cdot 2$			
Eye	13	1.4	Vulva	4	1.2^{-2}			
Corpus uteri .	11	$1 \cdot 2$	Thyroid	4	1.2			
Chorion-epithe-	10	1.1	Salivary gland .	ì	$1.2 \\ 1.2$			
lioma	10	1 1	Sanvary glanu .	1	1.7	•		
Mouth	9	1.0						
+ T 1		1.0						

[†] Tumours less than 1·0 per cent are not included in this table.
† Europeans from Lourenço Marques included for comparison.
* Denotes both sexes.

are more frequent than in any other part of Africa from which information is available. Furthermore, having regard to the imperfections of the statistical information, there is more than suggestive evidence that liver cancer in males and primary carcinoma of the cervix in females still constitute a pan-African problem in such remotely separated regions as Kampala and Johannesburg. The surprisingly high frequency ratio of cancer of the stomach in African males in Johannesburg and of carcinoma of the oesophagus, bronchus and lungs in males in Johannesburg and Durban suggest that an environmental rather than a genetic factor is at play in the aetiology of these cancers.

Although there are many features in common in the frequency ratio of cancer in various parts of Africa, there is also sufficient diversity to suggest that selection of specific areas for more intensive study might provide much valuable information about the possible aetiological factors responsible for the difference in the susceptibility to cancer of the various organs of the body. In view of the rapidly changing socio-economic conditions in Africa, it is urgent that aetiological studies be initiated without delay lest the opportunity be lost of probing the aetiology of those types of tumours which are afflicting populations not only in the western world but also in Africa and in Asia.

SUMMARY

An analysis has been presented of 1977 malignant neoplasms diagnosed at autopsy and by histological examination and accumulated over a period of 13 years in the Province of Mozambique, Portuguese East Africa. Of these tumours, 1273 were derived from Africans, 580 from Europeans and 124 from other ethnic groups.

Attention was drawn to the high frequency ratio of carcinoma of the liver in African males and to the fact that 73.5 per cent of all malignant neoplasms occurred in four sites, namely, the liver (43.1 per cent), the skin (13.9 per cent), lymphoid tissues (8.6 per cent) and urinary bladder (7.9 per cent). Carcinoma of the oesophagus, stomach, colon and rectum, lung and bronchus were remarkably low in the African as compared with European males living in Mozambique. Carcinoma of the cervix uteri was the commonest tumour (20.6 per cent) in African females and together with carcinoma of the liver (14.6 per cent), skin (13.9 per cent), and bladder (7.2 per cent) was responsible for 56.3 per cent of all malignancies as compared with 36.6 per cent of tumours in comparable sites in European females. Noteworthy was the high frequency of cervical carcinoma as compared with carcinoma of the body of the uterus and the relatively low frequency of breast cancer (7.4 per cent) in African females.

This analysis disclosed that primary carcinoma of the liver was occurring with unusual frequency in young people although the age of maximum incidence could not be established before completion of the rates survey now in progress.

It became evident that in the absence of well established cancer registries, data accumulated from the hospital and routine pathology laboratory could provide a useful guide to the frequency ratio of various cancers in Africa. From a comparison of the data compiled in Lourenço Marques with that derived from other African territories, it was apparent (1) that amongst African males, primary liver cancer and in females, carcinoma of the cervix uteri, with two exceptions were the most frequently occurring malignant neoplasms and (2) that there were notable

differences in the frequency ratios of malignant neoplasms in different regions in Africa. The urgency for initiating aetiological studies to explore the basis for these differences was emphasized.

I wish to acknowledge my indebtedness to Professor Joseph Gillman for his stimulating encouragement and helpful advice and criticism during the progress of this work, and to Dr. Christine Gilbert for her invaluable assistance in the preparation of the manuscript.

I wish to thank the National Cancer Association of South Africa for a generous grant which is facilitating the accomplishment of the present study.

REFERENCES

BERMAN, C.—(1935) S. Afr. J. med. Sci., 1, 12.

Camain, R.—(1954) Bull. Mem. de l'Ecole Med et Pharm. Dakar, 2, 208.

DAVIES, J. N. P.—(1948) E. Afr. med J., 25, 117. DES LIGNERIS, M. J. A.—(1936) S. Afr. med. J., 10, 478.

ELMES, B. G. T. AND BALDWIN, R. E. T.—(1947) Ann. trop. Med. Parasit., 41, 321.

FINDLAY, G. M.—(1949) J. R. micr. Soc., 69, 166.

GELFAND, M.—(1948) 'The Sick African'. Capetown (Stewart). Higginson, J.—(1951) Cancer, 4, 1224.

PIRIE, J. H.—(1921) Med. J. S. Afr., 17, 87.

Prates, M.—(1938) 'Actas do 1° Cong. Med. de Lourenco Marques'. Set.

SMITH, E. C. AND ELMES, B. G. T.—(1934) Ann. trop. Med. Parasit., 28, 461.

STRACHAN, A. C.—(1934) J. Path. Bact., 39, 209.

Thijs, A.—(1957) Ann. Soc. belge Med. trop., 37, 483.

VINT, F. W.—(1935) Lancet, ii, 628.

Wainwright, J. and Roach, G. G.—(1957) S. Afr. Cancer Bull., 1, 162.